Monday, September 20, 2010
Monday, September 6, 2010
This last week in Biology I have been researching clinical trails. More specifically, I have been learning about a trail concerning prostate caner called, AVODART After Radical Therapy For Prostate Cancer Study. This study is still underway but I would be happy to share with you what I have learned so far.
This study was specifically designed to see if they discovered a new medicine to prolong the life of victims of prostate cancer after they have had radical treatment. This trial is a randomized double-blind, placebo-controlled experiment. This just means that to test Avodart (the drug that might cure cancer) the scientists are using placebo (a sugar pill) as the control. Or in other words, just something to compare it to. Making the experiment double-blind just means that the patients, caregivers, investigators, and outcomes assessor won't know whether the patient is being given Avodart or the placebo. Having a double-blind trail helps eliminate bias or false results.
To be eligible for this study the subject must be between the ages of 18 and 85. They also have to have prostate cancer and have undergone radical treatments to try and cure or get rid of it.
The subjects in the study (no matter what pills they are given) are instructed to take one tablet by mouth daily. They will be given a three month supply of pills every three months when they come for their scheduled clinic visit. All of the patients will do this for exactly 24 months.
After all the subjects have completed the two year trial the scientists will collaborate the results. The estimated study completion date is March 2011.
This study was specifically designed to see if they discovered a new medicine to prolong the life of victims of prostate cancer after they have had radical treatment. This trial is a randomized double-blind, placebo-controlled experiment. This just means that to test Avodart (the drug that might cure cancer) the scientists are using placebo (a sugar pill) as the control. Or in other words, just something to compare it to. Making the experiment double-blind just means that the patients, caregivers, investigators, and outcomes assessor won't know whether the patient is being given Avodart or the placebo. Having a double-blind trail helps eliminate bias or false results.
To be eligible for this study the subject must be between the ages of 18 and 85. They also have to have prostate cancer and have undergone radical treatments to try and cure or get rid of it.
The subjects in the study (no matter what pills they are given) are instructed to take one tablet by mouth daily. They will be given a three month supply of pills every three months when they come for their scheduled clinic visit. All of the patients will do this for exactly 24 months.
After all the subjects have completed the two year trial the scientists will collaborate the results. The estimated study completion date is March 2011.
Subscribe to:
Posts (Atom)